Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • fat.cells fat.cells Oct 27, 2012 3:57 PM Flag

    Twelve Reasons to stay with ARNA - including 40 million shorts sitting inside the Titanic

    1 EU rejection for Vivus will only benefit Arena.

    2. Milestone payments from Eisai will boost Arena’s cash flow.

    3. ARNA's other rival is still wearing diapers - needs daily milk from analysts

    4 Lorcaserin lowered total cholesterol, LDL, and triglyceride levels compared to the placebo group at Year 1 of its BLOOM trial Yeah...that is right!

    5. Arena has plenty of cash and will have more cash after DEA scheduling is complete.

    6 Health insurers would benefit from the 8% weight-loss of Arena’s drug.

    7 Not addictive like other prescription medicines

    8 No patent worries

    9 ARNA has a New drug in the pipeline

    10. Naysayers are going out of the way to critizize ARNA with false information round the clock

    11. Analysts downgrade it on a daily basis with false information or old information

    12 40 million shorts sitting inside the Titanic

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ARNA
4.4991-0.0709(-1.55%)3:25 PMEDT